These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35588376)

  • 1. Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potency.
    Frumento N; Figueroa A; Wang T; Zahid MN; Wang S; Massaccesi G; Stavrakis G; Crowe JE; Flyak AI; Ji H; Ray SC; Shaw GM; Cox AL; Bailey JR
    J Clin Invest; 2022 Aug; 132(15):. PubMed ID: 35588376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2.
    Colbert MD; Flyak AI; Ogega CO; Kinchen VJ; Massaccesi G; Hernandez M; Davidson E; Doranz BJ; Cox AL; Crowe JE; Bailey JR
    J Virol; 2019 Jul; 93(14):. PubMed ID: 31068427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development.
    Salas JH; Urbanowicz RA; Guest JD; Frumento N; Figueroa A; Clark KE; Keck Z; Cowton VM; Cole SJ; Patel AH; Fuerst TR; Drummer HE; Major M; Tarr AW; Ball JK; Law M; Pierce BG; Foung SKH; Bailey JR
    Gastroenterology; 2022 Feb; 162(2):562-574. PubMed ID: 34655573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing antibodies evolve to exploit vulnerable sites in the HCV envelope glycoprotein E2 and mediate spontaneous clearance of infection.
    Frumento N; Sinnis-Bourozikas A; Paul HT; Stavrakis G; Zahid MN; Wang S; Ray SC; Flyak AI; Shaw GM; Cox AL; Bailey JR
    Immunity; 2024 Jan; 57(1):40-51.e5. PubMed ID: 38171362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.
    Swann RE; Cowton VM; Robinson MW; Cole SJ; Barclay ST; Mills PR; Thomson EC; McLauchlan J; Patel AH
    J Virol; 2016 May; 90(9):4530-4543. PubMed ID: 26912610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Convergent evolution and targeting of diverse E2 epitopes by human broadly neutralizing antibodies are associated with HCV clearance.
    Ogega CO; Skinner NE; Schoenle MV; Wilcox XE; Frumento N; Wright DA; Paul HT; Sinnis-Bourozikas A; Clark KE; Figueroa A; Bjorkman PJ; Ray SC; Flyak AI; Bailey JR
    Immunity; 2024 Apr; 57(4):890-903.e6. PubMed ID: 38518779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1.
    El-Diwany R; Cohen VJ; Mankowski MC; Wasilewski LN; Brady JK; Snider AE; Osburn WO; Murrell B; Ray SC; Bailey JR
    PLoS Pathog; 2017 Feb; 13(2):e1006235. PubMed ID: 28235087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A panel of hepatitis C virus glycoproteins for the characterization of antibody responses using antibodies with diverse recognition and neutralization patterns.
    Chumbe A; Grobben M; Capella-Pujol J; Koekkoek SM; Zon I; Slamanig S; Merat SJ; Beaumont T; Sliepen K; Schinkel J; van Gils MJ
    Virus Res; 2024 Mar; 341():199308. PubMed ID: 38171391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
    Urbanowicz RA; McClure CP; Brown RJ; Tsoleridis T; Persson MA; Krey T; Irving WL; Ball JK; Tarr AW
    J Virol; 2015 Dec; 90(7):3288-301. PubMed ID: 26699643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taking cues from convalescence to improve vaccines against hepatitis C virus.
    Sreekumar BK; Taha TY; Ott M
    J Clin Invest; 2022 Aug; 132(15):. PubMed ID: 35912856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.
    Wong JA; Bhat R; Hockman D; Logan M; Chen C; Levin A; Frey SE; Belshe RB; Tyrrell DL; Law JL; Houghton M
    J Virol; 2014 Dec; 88(24):14278-88. PubMed ID: 25275133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.
    Gu J; Hardy J; Boo I; Vietheer P; McCaffrey K; Alhammad Y; Chopra A; Gaudieri S; Poumbourios P; Coulibaly F; Drummer HE
    J Virol; 2018 May; 92(9):. PubMed ID: 29467319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs.
    Vietheer PT; Boo I; Gu J; McCaffrey K; Edwards S; Owczarek C; Hardy MP; Fabri L; Center RJ; Poumbourios P; Drummer HE
    Hepatology; 2017 Apr; 65(4):1117-1131. PubMed ID: 27997681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms.
    Mankowski MC; Kinchen VJ; Wasilewski LN; Flyak AI; Ray SC; Crowe JE; Bailey JR
    Proc Natl Acad Sci U S A; 2018 Jan; 115(1):E82-E91. PubMed ID: 29255018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.
    Chmielewska AM; Naddeo M; Capone S; Ammendola V; Hu K; Meredith L; Verhoye L; Rychlowska M; Rappuoli R; Ulmer JB; Colloca S; Nicosia A; Cortese R; Leroux-Roels G; Balfe P; Bienkowska-Szewczyk K; Meuleman P; McKeating JA; Folgori A
    J Virol; 2014 May; 88(10):5502-10. PubMed ID: 24599994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype.
    Tarr AW; Urbanowicz RA; Hamed MR; Albecka A; McClure CP; Brown RJ; Irving WL; Dubuisson J; Ball JK
    J Virol; 2011 May; 85(9):4246-57. PubMed ID: 21325403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered Glycosylation Patterns Increase Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing Antibodies Which Confer Protection in Mice.
    Li D; von Schaewen M; Wang X; Tao W; Zhang Y; Li L; Heller B; Hrebikova G; Deng Q; Ploss A; Zhong J; Huang Z
    J Virol; 2016 Dec; 90(23):10486-10498. PubMed ID: 27630242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection.
    Kinchen VJ; Zahid MN; Flyak AI; Soliman MG; Learn GH; Wang S; Davidson E; Doranz BJ; Ray SC; Cox AL; Crowe JE; Bjorkman PJ; Shaw GM; Bailey JR
    Cell Host Microbe; 2018 Nov; 24(5):717-730.e5. PubMed ID: 30439341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.
    Logan M; Law J; Wong JAJ; Hockman D; Landi A; Chen C; Crawford K; Kundu J; Baldwin L; Johnson J; Dahiya A; LaChance G; Marcotrigiano J; Law M; Foung S; Tyrrell L; Houghton M
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses.
    Ren Y; Min YQ; Liu M; Chi L; Zhao P; Zhang XL
    Biochim Biophys Acta; 2016 Aug; 1860(8):1764-75. PubMed ID: 26278021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.